var data={"title":"Enalapril: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Enalapril: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6100?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=enalapril-drug-information\" class=\"drug drug_general\">see &quot;Enalapril: Drug information&quot;</a> and <a href=\"topic.htm?path=enalapril-patient-drug-information\" class=\"drug drug_patient\">see &quot;Enalapril: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708730\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Fetal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">When pregnancy is detected, discontinue enalapril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164751\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Epaned;</li>\n      <li>Vasotec</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50667923\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vasotec</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13732756\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Angiotensin-Converting Enzyme (ACE) Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13732924\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">Use lower listed initial dose in patients with hyponatremia, hypovolemia, severe CHF, decreased renal function, or in those receiving diuretics</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Oral: Initial: 0.04 to 0.1 mg/kg/day every 24 hours; initiate at the lower end of the range and titrate to effect as required every few days; hypotension and oliguria have been associated with initial doses of 0.1 mg/kg (Dutta 2003; Lindle 2014; Schilder 1995); maximum reported dose: 0.27 mg/kg/day (Leversha 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b>  Use in neonates with GFR &lt;30 mL/minute/1.73 m<sup>2</sup> is not recommended; no dosing data available</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13732764\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=enalapril-drug-information\" class=\"drug drug_general\">see &quot;Enalapril: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Use lower listed initial dose in patients with hyponatremia, hypovolemia, severe CHF, decreased renal function, or in those receiving diuretics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heart Failure:</b> Limited data available: Infants, Children and Adolescents: Oral: Initial: 0.1 mg/kg/day in 1 to 2 divided doses; increase as required over 2 weeks to maximum of 0.5 mg/kg/day; mean dose required for CHF improvement in 39 children (age range: 9 days to 17 years) was 0.36 mg/kg/day; select individuals have been treated with doses up to 0.94 mg/kg/day (Leversha 1994; Momma 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension:</b> Infants, Children and Adolescents: Oral: Initial: 0.08 mg/kg/dose once daily (maximum dose: 5 mg); adjust dose according to blood pressure readings; doses &gt;0.58 mg/kg (or &gt;40 mg) have not been studied</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Proteinuria, nephrotic syndrome:</b> Limited data available: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dosing: Children &ge;7 years and Adolescents: 2.5 to 5 mg/day was reported in a retrospective study in normotensive pediatric patients as either monotherapy (n=17; mean age: 13.7 years; range: 8 to 17 years) or with prednisone (n=11; mean age: 12.6 years; range: 7 to 16 years); significant decrease in proteinuria (with or without nephrotic syndrome) occurred; no significant change in blood pressure was observed (Sasinka 1999); a case series of three adolescents with sickle anemia  nephropathy reported an initial dose of 5 mg/day; one patient required an increase to 7.5 mg/day (Fitzhugh 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: Children and Adolescents: Initial: 0.2 mg/kg/day; titrate to response at 4- to 12-week intervals; range: 0.2 to 0.6 mg/kg/day; maximum daily dose: 20 mg/<b>day</b>; a crossover dose comparison trial showed effects on proteinuria were dose-dependent (Bagga 2004; Chandar 2007; Delucchi 2000; Lama 2000; White 2003); if combined with other angiotensin blockade (ARB), lower doses have been reported (0.1 to 0.16 mg/kg/day) (Chandar 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asymptomatic left ventricular dysfunction:</b> Oral: Initial: 2.5 mg twice daily; increase as tolerated; usual dose: 20 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heart failure with reduced ejection fraction (HFrEF):</b> Oral: Initial: 2.5 mg once or twice daily (usual range: 5 to 40 mg/day in 2 divided doses); titrate slowly at 1- to 2-week intervals. Target dose: 10 to 20 mg twice daily (ACCF/AHA [Yancy 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension: </b>Oral: 2.5 to 5 mg daily then increase as required, usually at 1- to 2-week intervals; usual dose range (ASH/ISH [Weber 2014]): 10 to 40 mg daily. Target dose (JNC 8 [James 2013]): 20 mg daily in 1 or 2 divided doses. <b>Note:</b> Initiate with 2.5 mg if patient is taking a diuretic which cannot be discontinued. May add a diuretic if blood pressure cannot be controlled with enalapril alone.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling: Use in infants, children, and adolescents &le;16 years of age with GFR &lt;30 mL/minute/1.73 m<sup>2</sup> is not recommended; no dosing data available in this population</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 75% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 50% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;30 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &le;30 mL/minute: Administer 2.5 mg/day; titrate upward until blood pressure is controlled</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis (IHD): Moderately dialyzable (20% to 50%): Initial: 2.5 mg on dialysis days; adjust dose on nondialysis days depending on blood pressure response.</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">Alternate recommendations (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 50 mL/minute: Administer 50% to 100% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute: Administer 25% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis: Supplemental dose is not necessary, although some removal of drug occurs</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164720\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as maleate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epaned: 1 mg/mL (150 mL) [contains sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Oral, as maleate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epaned: 1 mg/mL (150 mL [DSC]) [contains methylparaben, propylparaben, saccharin sodium; berry-citrus flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as maleate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vasotec: 2.5 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vasotec: 2.5 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vasotec: 5 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vasotec: 5 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vasotec: 10 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vasotec: 10 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vasotec: 20 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vasotec: 20 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 5 mg, 10 mg, 20 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164704\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13732991\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May administer without regard to food </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21965335\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from freezing and excessive heat. May store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) for up to 60 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for oral solution kit: Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Do not freeze. Protect from moisture. Once reconstituted, the solution should be stored at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F) and may be stored for up to 60 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13732757\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of hypertension (FDA approved in ages 1 month to 16 years and adults), symptomatic heart failure (HF) (FDA approved in adults), and asymptomatic left ventricular dysfunction (FDA approved in adults); has also been used to treat proteinuria in steroid-resistant nephrotic syndrome patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164813\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Enalapril may be confused with Anafranil, Elavil, Eldepryl, ramipril</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Acepril [Hungary, Switzerland] may be confused with Accupril which is a brand name for quinapril [US, Canada, multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Acepril: Brand name for enalapril [Hungary, Switzerland], but also brand name for captopril [Great Britain]; lisinopril [Malaysia]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164810\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Chest pain, hypotension, orthostatic effect, orthostatic hypotension, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dysgeusia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased serum creatinine, renal insufficiency (in patients with bilateral renal artery stenosis or hypovolemia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bronchitis, cough, dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Acute generalized exanthematous pustulosis, agranulocytosis, alopecia, anaphylactoid reaction, angina pectoris, angioedema, anosmia, arthritis, asthma, ataxia, atrial fibrillation, atrial tachycardia, bone marrow depression, bradycardia, cardiac arrest, cardiac arrhythmia, cerebrovascular accident, cholestatic jaundice, confusion, conjunctivitis, depression, eosinophilia, eosinophilic pneumonitis, erythema multiforme, exfoliative dermatitis, giant-cell arteritis, gynecomastia, hallucination, hemolysis (with G6PD), herpes zoster, IgA vasculitis, increased erythrocyte sedimentation rate, intestinal obstruction, insomnia, interstitial nephritis, leukocytosis, lichenoid eruption, melena, myocardial infarction, myositis, neutropenia, ototoxicity, pancreatitis, pemphigus, pemphigus foliaceus, peripheral neuropathy, positive ANA titer, psychosis, pulmonary edema, pulmonary embolism, pulmonary infarct, pulmonary infiltrates, Raynaud's phenomenon, serositis, Sjogren's syndrome, skin photosensitivity, Stevens-Johnson syndrome, stomatitis, systemic lupus erythematosus, thrombocytopenia, toxic epidermal necrolysis, upper respiratory tract infection, vasculitis, visual hallucination (Doane, 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164728\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to enalapril or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; idiopathic or hereditary angioedema; concomitant use with aliskiren in patients with diabetes mellitus; coadministration with or within 36 hours of switching to or from a neprilysin inhibitor (eg, sacubitril).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for ACE inhibitors is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concomitant use with aliskiren-containing drugs in patients with moderate-to-severe renal impairment (GFR &lt;60 mL/minute/1.73 m<sup>2</sup>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164708\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans may be at an increased risk. Risk may also be increased with concomitant use of mTOR inhibitor (eg, everolimus) therapy or a neprilysin inhibitor (eg, sacubitril). Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with idiopathic or hereditary angioedema or previous angioedema associated with ACE inhibitor therapy is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis (some fatal); discontinue if marked elevation of hepatic transaminases or jaundice occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1 to 4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with HF) and excluded prior to discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Another ACE inhibitor, captopril, has been associated with neutropenia with myeloid hypoplasia and agranulocytosis; anemia and thrombocytopenia have also occurred. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses). Effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation. Close monitoring of patient is required, especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use, especially in patients with HF where a reduction in systolic blood pressure is a desirable observation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, HF) whose GFR is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function (Bakris 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition (ACCF/AHA [Gersh 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal artery stenosis: Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in preexisting renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Black patients: ACE inhibitors effectiveness is less in black patients than in non-blacks. In addition, ACE inhibitors cause a higher rate of angioedema in black than in non-black patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: In patients on chronic ACE inhibitor therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension. However, discontinuation of therapy prior to surgery is controversial. If continued preoperatively, avoidance of hypotensive agents during surgery is prudent (Hillis 2011). Based on current research and clinical guidelines in patients undergoing non-cardiac surgery, continuing ACE inhibitors is reasonable in the perioperative period. If ACE inhibitors are held before surgery, it is reasonable to restart postoperatively as soon as clinically feasible (ACC/AHA [Fleisher 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage forms specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral solution: May contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol. Large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982). Some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25872259\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In pediatric patients, an isolated dry hacking cough lasting &gt;3 weeks was reported in seven of 42 pediatric patients (17%) receiving ACE inhibitors (von Vigier 2000); a review of pediatric randomized-controlled ACE inhibitor trials reported a lower incidence of 3.2% (Baker-Smith 2010). Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">ACE inhibitors have been associated with nephrotoxicity in neonates, risk may be higher in preterm neonates; a retrospective study evaluated ACE inhibitor (captopril or enalapril) nephrotoxicity in 206 neonates (term [n=168] and preterm [n=38]) with cardiovascular disease; nearly 42% of neonates were in the pRIFLE category of risk or higher; 30% of all patients were in the renal failure category; when separated out into term and preterm, &gt;50% of preterm neonates were in the renal failure category while receiving an ACE inhibitor and were significantly more likely to be in the renal failure category compared to term neonates (Lindle 2014). Initiate dosing at lower end of the range in preterm neonates. Severe hypotension was reported in a <b>preterm</b> neonate (birth weight: 835 g, gestational age: 26 weeks, postnatal age: 9 days) who was treated with enalapril 0.1 mg/kg orally; hypotension responded to IV plasma and dopamine; the authors suggest starting enalapril in preterm infants at 0.01 mg/kg and increasing upwards in a stepwise fashion with very close monitoring of blood pressure and urine output. However, in this case report, oral enalapril at doses of 0.01 mg/kg to 0.04 mg/kg did not adequately control blood pressure (Schilder 1995).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164797\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164713\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=83360&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Management: Aliskiren use with ACEIs or ARBs in patients with diabetes is contraindicated. Combined use in other patients should be avoided, particularly when CrCl is less than 60 mL/min. If combined, monitor potassium, creatinine, and blood pressure closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: Angiotensin-Converting Enzyme Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II: Angiotensin-Converting Enzyme Inhibitors may enhance the therapeutic effect of Angiotensin II. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Angiotensin II Receptor Blockers may increase the serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: In US labeling, use of telmisartan and ramipril is not recommended. It is not clear if any other combination of an ACE inhibitor and an ARB would be any safer. Consider alternatives to the combination when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprotinin: May diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: Angiotensin-Converting Enzyme Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canagliflozin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Canagliflozin may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): Angiotensin-Converting Enzyme Inhibitors may enhance the arrhythmogenic effect of Ciprofloxacin (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipeptidyl Peptidase-IV Inhibitors: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Drospirenone: Angiotensin-Converting Enzyme Inhibitors may enhance the hyperkalemic effect of Drospirenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ferric Gluconate: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ferric Hydroxide Polymaltose Complex: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Hydroxide Polymaltose Complex. Specifically, the risk for angioedema or allergic reactions may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gelatin (Succinylated): Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Gelatin (Succinylated). Specifically, the risk of a paradoxical hypotensive reaction may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gold Sodium Thiomalate: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grass Pollen Allergen Extract (5 Grass Extract): Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). Specifically, ACE inhibitors may increase the risk of severe allergic reaction to Grass Pollen Allergen Extract (5 Grass Extract). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Icatibant: May diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Dextran Complex: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Angiotensin-Converting Enzyme Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Salts: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pregabalin: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sacubitril: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Sacubitril. Specifically, the risk of angioedema may be increased with this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: Angiotensin-Converting Enzyme Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: May enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164731\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">\n      <b>[US Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.</b> Enalapril crosses the placenta; the active metabolite enalaprilat can be detected in the newborn (Schubiger 1988).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. The use of these drugs in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Teratogenic effects may occur following maternal use of an ACE inhibitor during the first trimester, although this finding may be confounded by maternal disease. Because adverse fetal events are well documented with exposure later in pregnancy, ACE inhibitor use in pregnant women is not recommended (Seely 2014; Weber 2014). Infants exposed to an ACE inhibitor in utero should be monitored for hyperkalemia, hypotension, and oliguria. Oligohydramnios may not appear until after irreversible fetal injury has occurred. Exchange transfusions or dialysis may be required to reverse hypotension or improve renal function, although data related to the effectiveness in neonates is limited.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant and mother. ACE inhibitors are not recommended for the treatment of uncomplicated hypertension in pregnancy (ACOG 2013) and they are specifically contraindicated for the treatment of hypertension and chronic heart failure during pregnancy by some guidelines (Regitz-Zagrosek 2011). In addition, ACE inhibitors should generally be avoided in women of reproductive age (ACOG 2013). If treatment for hypertension or chronic heart failure in pregnancy is needed, other agents should be used (ACOG 2013; Regitz-Zagrosek 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13732765\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, renal function, WBC, serum potassium, serum glucose; monitor for angioedema and anaphylactoid reactions </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164707\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164727\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: 55% to 75%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~50% (Davies 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Prodrug, undergoes hepatic biotransformation to enalaprilat</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Enalapril: CHF: Neonates (n=3, PNA: 10 to 19 days): 10.3 hours (range: 4.2 to 13.4 hours) (Nakamura 1994); CHF: Infants and Children &le;6.5 years of age (n=11): 2.7 hours (range: 1.3 to 6.3 hours) (Nakamura 1994); Adults: Healthy: 2 hours; CHF: 3.4 to 5.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Enalaprilat: CHF: Neonates (n=3, PNA: 10 to 19 days): 11.9 hours (range: 5.9 to 15.6 hours) (Nakamura 1994); CHF: Infants and Children &le;6.5 years of age (n=11): 11.1 hours (range: 5.1 to 20.8 hours) (Nakamura 1994); Infants 6 weeks to 8 months of age: 6 to 10 hours (Lloyd 1989); Adults: ~35 hours (Till 1984; Ulm 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: Enalapril: 0.5 to 1.5 hours; Enalaprilat (active metabolite): 3 to 4.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (61%; 18% of which was enalapril, 43% was enalaprilat); feces (33%; 6% of which was enalapril, 27% was enalaprilat) (Ulm 1982)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164726\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Commercial oral solution kit is available (1 mg/mL).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 1 mg/mL oral suspension may be made with tablets, Bicitra [discontinued] or equivalent, and Ora-Sweet SF. Place ten 20 mg tablets in a 200 mL polyethylene terephthalate bottle; add 50 mL of Bicitra [discontinued] or equivalent and shake well for at least 2 minutes. Let stand for 1 hour then shake for 1 additional minute; add 150 mL of Ora-Sweet SF and shake well. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 30 days when stored in a polyethylene terephthalate bottle and refrigerated (Vasotec prescribing information, 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 1 mg/mL oral suspension may be made with tablets and one of three different vehicles (cherry syrup, a 1:1 mixture of Ora-Sweet and Ora-Plus, or a 1:1 mixture of Ora-Sweet SF and Ora-Plus). Crush six 20 mg tablets in a mortar and reduce to a fine powder. Add 15 mL of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;protect from light&rdquo;. Stable for 60 days when stored in amber plastic prescription bottles in the dark at room temperature or refrigerated (Allen 1998).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 1 mg/mL oral suspension may be made with tablets and one of three different vehicles (deionized water, citrate buffer solution at pH 5.0, or a 1:1 mixture of Ora-Sweet and Ora-Plus). Crush twenty 10 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to <b>almost</b> 200 mL; transfer to a graduated cylinder, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label &quot;shake well&quot; and &quot;protect from light&quot;. Preparations made in citrate buffer solution at pH 5.0 and the 1:1 mixture of Ora-Sweet and Ora-Plus are stable for 91 days when stored in plastic prescription bottles in the dark at room temperature or refrigerated. Preparation made in deionized water is stable for 91 days refrigerated or 56 days at room temperature when stored in plastic prescription bottles in the dark. <b>Note:</b> To prepare the isotonic citrate buffer solution (pH 5.0), see reference (Nahata 1998).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A more dilute, 0.1 mg/mL oral suspension may be made with tablets and an isotonic buffer solution at pH 5.0. Grind one 20 mg tablet in a glass mortar and reduce to a fine powder; mix with isotonic citrate buffer (pH 5.0) and filter; add quantity of buffer solution sufficient to make 200 mL. Label &quot;shake well&quot;, &quot;protect from light&quot;, and &quot;refrigerate&quot;. Stable for 90 days (Boulton 1994).</p>\n    <div class=\"reference\">Allen LV Jr and Erickson MA 3rd. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. <i>Am J Health Syst Pharm.</i> 1998;55(18):1915-1920.<span class=\"pubmed-id\">9784772</span></div>\r\n\n    <div class=\"reference\">Boulton DW, Woods DJ, Fawcett JP, et al. The stability of an enalapril maleate oral solution prepared from tablets. <i>Aust J Hosp Pharm.</i> 1994;24(2):151-156.</div>\r\n\n    <div class=\"reference\">Nahata MC, Morosco RS, and Hipple TF. Stability of enalapril maleate in three extemporaneously prepared oral liquids. <i>Am J Health Syst Pharm.</i> 1998;55(11):1155-1157.<span class=\"pubmed-id\">9626379</span></div>\r\n\n    <div class=\"reference\">Vasotec prescribing information, Valeant Pharmaceuticals North America LLC: Bridgewater, NJ; 2017.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164730\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Epaned Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (150 mL): $590.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Enalapril Maleate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $145.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $154.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $194.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $276.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Vasotec Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (30): $498.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $578.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (90): $1,908.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $2,715.95</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164734\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acebitor (PH);</li>\n      <li>Acetec (MY);</li>\n      <li>Acetensil (ES);</li>\n      <li>Alapren (ZA);</li>\n      <li>Amprace (NZ);</li>\n      <li>Analept (GR);</li>\n      <li>Anapril (BD, SG, TH);</li>\n      <li>Anapril S Minitab (TH);</li>\n      <li>Angiotec (JO, QA, SA);</li>\n      <li>Angonic (VN);</li>\n      <li>Antens (ET, KR);</li>\n      <li>Apridal (PY);</li>\n      <li>Auspril (AU);</li>\n      <li>Bajaten (CL);</li>\n      <li>Baripril (ES);</li>\n      <li>Bealipril (LV);</li>\n      <li>Beartec (KR);</li>\n      <li>Benalipril (DE);</li>\n      <li>Berlipril (BG, HR);</li>\n      <li>Biocronil (CO);</li>\n      <li>Bonapress (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>BQL (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Converten (IN);</li>\n      <li>Convertin (IL);</li>\n      <li>Corodil (DK);</li>\n      <li>Crinoren (ES);</li>\n      <li>Dabonal (ES);</li>\n      <li>Danssan (MY);</li>\n      <li>Dynapril (PH);</li>\n      <li>Ednyt (BB, BM, BS, BZ, GY, HU, JM, LV, SR, TT);</li>\n      <li>Elfonal (KR);</li>\n      <li>Enace (TH);</li>\n      <li>Enahexal (NZ);</li>\n      <li>Enalagamma (DE);</li>\n      <li>Enalapril (ES);</li>\n      <li>Enaloc (FI);</li>\n      <li>Enam (LK, UA);</li>\n      <li>Enap (HK, HR, HU, IE, LV, RO, SG, SI, SK, UA);</li>\n      <li>Enap i.v. (HR);</li>\n      <li>Enap [inj.] (HU);</li>\n      <li>Enaprel (ET);</li>\n      <li>Enapren (IT);</li>\n      <li>Enapril (ZW);</li>\n      <li>Enaprin (KR);</li>\n      <li>Enaril (BD, KR, TH);</li>\n      <li>Enatec (BB, BM, BS, BZ, GY, JM, SR, TT);</li>\n      <li>Enazil (PL);</li>\n      <li>Enbid-20 (PH);</li>\n      <li>Enetil (CO);</li>\n      <li>Enpril (KR);</li>\n      <li>Entab (LK);</li>\n      <li>Envas (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Eril (BD);</li>\n      <li>Glioten (BR, EC, PE, PY, SG);</li>\n      <li>Grifopil (CL);</li>\n      <li>Herten (ES);</li>\n      <li>Hypace (PH);</li>\n      <li>Hyperil (KR);</li>\n      <li>Hypril (PH);</li>\n      <li>Hytrol (IN);</li>\n      <li>Ileveran (MX);</li>\n      <li>Innovace (GB, IE);</li>\n      <li>Invoril (AE, BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SG, SL, SN, TH, TN, TZ, UG, ZM, ZW);</li>\n      <li>Istopril (TR);</li>\n      <li>Kalpiren (MT);</li>\n      <li>Kaparlon-S (MT);</li>\n      <li>Korandil (ET, MT, TR, ZW);</li>\n      <li>Lapril (JO, QA, SA, TH);</li>\n      <li>Lenipril (KR);</li>\n      <li>Lotrial (AR, CR, DO, GT, HN, NI, PA, PE, SV, UY);</li>\n      <li>Macpril (LK);</li>\n      <li>Meipril (ID);</li>\n      <li>Naprilate (PH);</li>\n      <li>Naprilene (IT);</li>\n      <li>Narapril (AE, KR);</li>\n      <li>Neopril (KR);</li>\n      <li>Nuril (IN);</li>\n      <li>Olivin (HR);</li>\n      <li>Perisafe (TW);</li>\n      <li>Pres (DE);</li>\n      <li>Presil (CO);</li>\n      <li>Prilace (EC);</li>\n      <li>Rapril (KR);</li>\n      <li>Renacardon (ID);</li>\n      <li>Renallapin (KR);</li>\n      <li>Renite (PH);</li>\n      <li>Renite XL (PH);</li>\n      <li>Renitec (AE, AR, AT, AU, BE, BF, BG, BH, BJ, BR, CI, CN, CO, CY, CZ, EC, EE, EG, ES, ET, FI, FR, GH, GM, GN, GR, HU, JO, KE, KW, LB, LR, LU, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, NZ, PE, PH, PK, PT, QA, SA, SC, SD, SE, SL, SN, TN, TR, TW, TZ, UG, VE, VN, ZM, ZW);</li>\n      <li>Renitek (RU, UA);</li>\n      <li>Reniten (CH);</li>\n      <li>Renivace (JP);</li>\n      <li>Rennimed (ZW);</li>\n      <li>Sintec (TW);</li>\n      <li>Tenace (ID);</li>\n      <li>Tenaten (ID);</li>\n      <li>Unipril (CO);</li>\n      <li>Vasonorm (LK);</li>\n      <li>Vasopress (PH);</li>\n      <li>Vasopril (AE, BD, JO, QA);</li>\n      <li>Xanef (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&rsquo; Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/24150027 /pubmed\" target=\"_blank\" id=\"24150027 \">24150027 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bagga A, Mudigoudar BD, Hari P, et al, &quot;Enalapril Dosage in Steroid-Resistant Nephrotic Syndrome,&quot; <i>Pediatr Nephrol</i>, 2004, 19(1):45-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/14648339/pubmed\" target=\"_blank\" id=\"14648339\">14648339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baker-Smith CM, Benjamin DK Jr, Califf RM, et al, &quot;Cough in Pediatric Patients Receiving Angiotensin-Converting Enzyme Inhibitor Therapy or Angiotensin Receptor Blocker Therapy in Randomized Controlled Trials,&quot; <i>Clin Pharmacol Ther</i>, 2010, 87(6):668-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/20130570/pubmed\" target=\"_blank\" id=\"20130570\">20130570</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown NJ, Ray WA, Snowden M, et al, &quot;Black Americans Have an Increased Rate of Angiotensin Converting Enzyme Inhibitor-Associated Angioedema,&quot; <i>Clin Pharmacol Ther</i>, 1996, 60(1):8-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/8689816/pubmed\" target=\"_blank\" id=\"8689816\">8689816</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bult Y and van den Anker J, &ldquo;Hypertension in a Preterm Infant Treated With Enalapril,&rdquo; <i>J Pediatr Pharm Pract</i>, 1997, 2(4):229-31.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chandar J, Abitbol C, Montan&eacute; B, et al, &quot;Angiotensin Blockade as Sole Treatment for Proteinuric Kidney Disease in Children,&quot; <i>Nephrol Dial Transplant</i>, 2007, 22(5):1332-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/17299000/pubmed\" target=\"_blank\" id=\"17299000\">17299000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies RO, Gomez HJ, Irvin JD, Walker JF. An overview of the clinical pharmacology of enalapril. <i>Br J Clin Pharmacol</i>. 1984;18(Suppl 2):215S-229S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/6099737/pubmed\" target=\"_blank\" id=\"6099737\">6099737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Delucchi A, Cano F, Rodriguez E, et al, &quot;Enalapril and Prednisone in Children With Nephrotic-Range Proteinuria,&quot; <i>Pediatr Nephrol</i>, 2000, 14(12):1088-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/11045392/pubmed\" target=\"_blank\" id=\"11045392\">11045392</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doane J, Stults B. Visual hallucinations related to angiotensin-converting enzyme inhibitor use: case reports and review. <i>J Clin Hypertens (Greenwich)</i>. 2013;15(4):230-233.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/11045392/pubmed\" target=\"_blank\" id=\"11045392\">11045392</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dutta S and Narang A, &quot;Enalapril-Induced Acute Renal Failure in a Newborn Infant,&quot; <i>Pediatr Nephrol</i>, 2003, 18(6):570-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/12698328/pubmed\" target=\"_blank\" id=\"12698328\">12698328</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Epaned (enalapril) [prescribing information]. Greenwood Village, CO: Silvergate Pharmaceuticals Inc; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fitzhugh CD, Wigfall DR, and Ware RE, &quot;Enalapril and Hydroxyurea Therapy for Children With Sickle Nephropathy,&quot; <i>Pediatr Blood Cancer</i>, 2005, 45(7):982-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/15704213/pubmed\" target=\"_blank\" id=\"15704213\">15704213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frenneaux M, Stewart RA, Newman CM, et al, &quot;Enalapril for Severe Heart Failure in Infancy,&quot; <i>Arch Dis Child</i>, 1989, 64(2):219-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/2539059/pubmed\" target=\"_blank\" id=\"2539059\">2539059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2011;124(23):2610-2642.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/22064600/pubmed\" target=\"_blank\" id=\"22064600\">22064600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hogg RJ, Portman RJ, Milliner D, et al, &quot;Evaluation and Management of Proteinuria and Nephrotic Syndrome in Children: Recommendations From a Pediatric Nephrology Panel Established at the National Kidney Foundation Conference on Proteinuria, Albuminuria, Risk, Assessment, Detection, and Elimination (PARADE),&quot; <i>Pediatrics</i>, 2000, 105(6):1242-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/10835064/pubmed\" target=\"_blank\" id=\"10835064\">10835064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panelmembers appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lama G, Luongo I, Piscitelli A, et al, &quot;Enalapril: Antiproteinuric Effect in Children With Nephrotic Syndrome,&quot; <i>Clin Nephrol</i>, 2000, 53(6):432-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/10879662/pubmed\" target=\"_blank\" id=\"10879662\">10879662</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leversha AM, Wilson NJ, Clarkson PM, et al, &ldquo;Efficacy and Dosage of Enalapril in Congenital and Acquired Heart Disease,&rdquo; <i>Arch Dis Child</i>, 1994, 70(1):35-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/8110005/pubmed\" target=\"_blank\" id=\"8110005\">8110005</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindle KA, Dinh K, Moffett BS, et al. Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease. <i>Pediatr Cardiol</i>. 2014;35(3):499-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/24233240/pubmed\" target=\"_blank\" id=\"24233240\">24233240</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lloyd TR, Mahoney LT, Knoedel D, et al, &ldquo;Orally Administered Enalapril for Infants With Congestive Heart Failure: A Dose-Finding Study,&rdquo; <i>J Pediatr</i>, 1989, 114(4):650-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/2538615/pubmed\" target=\"_blank\" id=\"2538615\">2538615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Momma K, &quot;ACE Inhibitors in Pediatric Patients With Heart Failure,&quot; <i>Paediatr Drugs</i>, 2006, 8(1):55-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/16494512/pubmed\" target=\"_blank\" id=\"16494512\">16494512</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nakamura H, Ishii M, Sugimura T, et al, &ldquo;The Kinetic Profiles of Enalapril and Enalaprilat and Their Possible Developmental Changes in Pediatric Patients With Congestive Heart Failure,&rdquo; <i>Clin Pharmacol Ther</i>, 1994, 56(2):160-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/8062492/pubmed\" target=\"_blank\" id=\"8062492\">8062492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &quot;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&quot; <i>Pediatrics</i>, 2004, 114(2 Suppl):555-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regitz-Zagrosek V, Blomstrom Lundqvist C, et al. European Society of Gynecology (ESG). ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).<i> Heart J</i>. 2011;32(24):3147-3197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/21873418 /pubmed\" target=\"_blank\" id=\"21873418 \">21873418 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sasinka MA, Podracka L, Boor A, et al, &quot;Enalapril Treatment of Proteinuria in Normotensive Children,&quot; <i>Bratisl Lek Listy</i>, 1999, 100(9):476-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/10645036/pubmed\" target=\"_blank\" id=\"10645036\">10645036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schilder JL and Van den Anker JN, &quot;Use of Enalapril in Neonatal Hypertension,&quot; <i>Acta Paediatr</i>, 1995, 84(12):1426-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/8645963/pubmed\" target=\"_blank\" id=\"8645963\">8645963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schubiger G, Flury G, Nussberger J. Enalapril for pregnancy-induced hypertension: acute renal failure in a neonate. <i>Ann Intern Med</i>. 1988;108(2):215-216.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/2829674 /pubmed\" target=\"_blank\" id=\"2829674 \">2829674 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seely EW, Ecker J. Chronic hypertension in pregnancy. <i>Circulation</i>. 2014;129(11):1254-1261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/24637432 /pubmed\" target=\"_blank\" id=\"24637432 \">24637432 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Till AE, Gomez HJ, Hichens M, et al. Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers.<i> Biopharm Drug Dispos</i>. 1984;5(3):273-280.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/6091806 /pubmed\" target=\"_blank\" id=\"6091806 \">6091806 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ulm EH, Hichens M, Gomez HJ, et al. Enalapril maleate and a lysine analogue (MK-521): disposition in man. <i>Br J Clin Pharmacol</i>. 1982;14(3):357-362.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/6289858 /pubmed\" target=\"_blank\" id=\"6289858 \">6289858 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vasotec (enalapril) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    von Vigier RO, Mozzettini S, Truttmann AC, et al, &ldquo;Cough is Common in Children Prescribed Converting Enzyme Inhibitors,&rdquo; <i>Nephron</i>, 2000, 84(1):98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/10644922/pubmed\" target=\"_blank\" id=\"10644922\">10644922</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wells TG, Bunchman TE, and Kearns GL, &quot;Treatment of Neonatal Hypertension With Enalaprilat,&quot; <i>J Pediatr</i>, 1990, 117(4):664-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/2170612/pubmed\" target=\"_blank\" id=\"2170612\">2170612</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White CT, Macpherson CF, Hurley RM, et al, &quot;Antiproteinuric Effects of Enalapril and Losartan: A Pilot Study,&quot; <i>Pediatr Nephrol</i>, 2003, 18(10):1038-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/12920631/pubmed\" target=\"_blank\" id=\"12920631\">12920631</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enalapril-pediatric-drug-information/abstract-text/12920631/pubmed\" target=\"_blank\" id=\"12920631\">12920631</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 83360 Version 186.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708730\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F164751\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50667923\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F13732756\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F13732924\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F13732764\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F164720\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F164704\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13732991\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F21965335\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13732757\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F164813\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F164810\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F164728\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F164708\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25872259\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F164797\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F164713\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F164731\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13732765\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F164707\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F164727\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F164726\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F164730\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F164734\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/83360|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=enalapril-drug-information\" class=\"drug drug_general\">Enalapril: Drug information</a></li><li><a href=\"topic.htm?path=enalapril-patient-drug-information\" class=\"drug drug_patient\">Enalapril: Patient drug information</a></li></ul></div></div>","javascript":null}